Owing to the complexities associated with the production of
biologics, biopharmaceutical developers are likely to continue relying on
contract service providers for various aspects of their respective product
development programs
London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Biomanufacturing Market, (4th
Edition), 2020-2030”
report to its list of offerings.
Given the rising
popularity of biologics and the 8,000+ such product candidates under clinical investigation,
the opportunity for contract manufacturing service providers engaged in this
domain, is high and anticipated to persist in the mid-long term, as well. In
fact, since 2000, over 120 new CMOs have been established, offering a variety
of cost-efficient manufacturing services and solutions to biologic developers.
To
order this 780+ page report, which features 300+ figures and 270+ tables,
please visit this - https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html
Key Market Insights
Presently, 225 CMOs,
possessing over 380 manufacturing facilities, claim to offer manufacturing
services for biopharmaceutical products
The manufacturing
services market for biopharmaceuticals is highly
fragmented, featuring a mix of small, mid-sized, large and very large players.
It is worth mentioning that more than 60% of CMOs mentioned in the report, have
the necessary capabilities to manufacture biologics across all scales of
operation.
More than 65% of service providers offer manufacturing
services for recombinant proteins and peptides
Close to 58% of CMOs
claim to have the required capabilities to offer antibody manufacturing
services. It is worth mentioning that a number of biologics manufacturers are
presently offering services related to the niche and emerging classes of
biologics.
Over 620 partnerships
were established in this domain, during the period 2015-2020
Majority of the deals
(~24%) recorded in the report, were established in 2020, primarily driven by
the investigational biologic drugs against COVID-19. Further, a large number
(~35%) of the partnerships were observed to be focused on the manufacturing of
biologics, followed by product development and manufacturing agreements (22%).
Currently, the
installed biopharmaceutical contract manufacturing capacity is estimated to be
~3.9 million liters, which is gradually being expanded
In order to meet the
growing demand for biologics, 177 expansion projects were undertaken by CMOs
between 2016 and 2020 Of the aforementioned initiatives, more than 40% were
focused on the establishment of new facilities, followed by the expansion of
existing manufacturing facilities (24%).
North America and
Europe are anticipated to capture 75% share (in terms of service revenues)
of the market, by 2030
At present, close to
90% of the total revenues are generated from projects involving commercialized
biologic products, and this trend is unlikely to change significantly in the
short to mid-term. Further, it is worth mentioning that the contract biomanufacturing
market for biologics in the Middle East and North Africa is anticipated to grow
at a relatively faster rate (13.6%), followed by the Asia-Pacific market
(11.2%).
To request a sample copy / brochure of this report, please visit
this - https://www.rootsanalysis.com/reports/250/request-sample.html
The USD 34.2 billion (by 2030) financial
opportunity within the biopharmaceutical contract manufacturing market has been
analyzed across the following segments:
§ Commonly
outsourced business operations
§ API
§ FDF
§ Types
of Expression Systems Used
§
Mammalian
§
Microbial
§ Others
§ Scale
of Operation
§ Preclinical
/ Clinical
§ Commercial
§ Company
Size
§ Small
§ Mid-sized
§ Large
/ Very Large
§ Types
of Biologics Manufactured
§ Antibody
Therapeutics
§ Vaccines
§ Cell
Therapies
§ Other
Biologics
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
§ Latin
America
§ Middle
East and North Africa
The report includes
profiles of key players (listed below) each profile features an overview
of the company, information related to its biologics focused service portfolio,
manufacturing facilities, recent developments, and an informed future outlook.
§
AGC Biologics
§
Boehringer Ingelheim
§
Catalent
§
Cytiva (GE Healthcare)
§
FUJIFILM Diosynth Biotechnologies
§
KBI Biopharma
§
Kemwell Biopharma
§
Lonza
§
Luina Bio
§
Novasep
§
Olon
§
Patheon
§
Piramal Pharma Solutions
§
Takara Bio
§
WuXi AppTec (WuXi Biologics)
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Vaccine Contract Manufacturing Market
(3rd Edition), 2021-2030
2.
ADC Contract Manufacturing Market (4th
Edition), 2020-2030
3.
Microbial Contract Manufacturing Market,
2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact
Details
Ben
Johnson
+1
(415) 800 3415
ben.johnson@rootsanalysis.com
Roots
Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
